Investment Rating - The investment rating for the company is "Outperform the Market" [5][3][16] Core Views - The company achieved a revenue of 3.026 billion yuan in 2024, representing a year-on-year growth of 5.45%, and a net profit of 1.958 billion yuan, with a year-on-year increase of 5.33% [1][7] - The company is focusing on expanding its product lines through external acquisitions, such as the planned acquisition of South Korean regenerative materials company REGEN Biotech, which will enhance its product layout and open up international sales channels [1][12] - The medical beauty industry has significant long-term penetration potential, and under compliance regulations, leading companies will further highlight their advantages [3][15] Financial Performance - In 2024, the gross profit margin was 94.64%, slightly down by 0.46 percentage points year-on-year, while the sales expense ratio remained stable at 9.15% [2][13] - The company maintained a stable operating cash flow of 1.927 billion yuan in 2024, reflecting good cash flow conditions [2][13] - The revenue growth forecast for 2025-2026 has been adjusted to 2.237 billion yuan and 2.618 billion yuan respectively, with a new forecast for 2027 set at 3.017 billion yuan [3][16] Product Performance - The revenue growth rates for solution and gel injection products were both around 5% in 2024, with revenue shares of 57.64% and 40.18% respectively [9][10] - The company has made progress in several pipeline products, including the review stage for botulinum products and clinical trial approval for semaglutide injection [1][9] Market Position - The company’s market capitalization is approximately 59.532 billion yuan, with a closing price of 196.74 yuan [5][17] - The company is positioned to leverage its existing product matrix to expand market share in the short term while combining self-research and external acquisitions for long-term growth [3][15]

Investment Rating - The investment rating for the company is "Outperform the Market" [5][3]. Core Views - The company is expected to achieve revenue growth of 5.45% year-on-year in 2024, reaching 3.0267 billion yuan, with a net profit of 1.9576 billion yuan, reflecting a growth of 5.33% [1][7]. - The company is actively expanding its product lines and international business through acquisitions, including a recent planned acquisition of South Korean REGEN Biotech to enhance its regenerative materials and open international sales channels [1][12]. - The medical beauty industry has significant long-term growth potential, and the company's strategy of combining self-research with external acquisitions is expected to provide new growth drivers for performance [3][15]. Financial Performance - In 2024, the gross profit margin is projected to be 94.64%, slightly down by 0.46 percentage points year-on-year, indicating stability despite increased industry price competition [2][13]. - The company maintains a stable operating cash flow of 1.927 billion yuan, reflecting good cash flow conditions [2][13]. - The revenue from solution and gel injection products is expected to grow at around 5%, maintaining their respective revenue shares of 57.64% and 40.18% [9][10]. Earnings Forecast - The forecast for net profit in 2025 and 2026 has been revised down to 2.237 billion yuan and 2.618 billion yuan, respectively, with a new estimate for 2027 at 3.017 billion yuan [3][16]. - The company’s earnings per share (EPS) is projected to be 6.47 yuan in 2024, increasing to 7.41 yuan in 2025 [4][19].